LAVA Therapeutics (NASDAQ:LVTX) Sees Large Decline in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 21,100 shares, a drop of 20.1% from the November 15th total of 26,400 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 61,100 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

Several research analysts recently commented on LVTX shares. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Leerink Partners restated a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday. Citizens Jmp cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, JMP Securities reiterated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, LAVA Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $4.67.

Institutional Trading of LAVA Therapeutics

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of LAVA Therapeutics during the 2nd quarter worth about $55,000. Pathway Financial Advisors LLC raised its holdings in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after acquiring an additional 42,500 shares during the period. Finally, Virtu Financial LLC acquired a new stake in LAVA Therapeutics during the third quarter worth approximately $32,000.

LAVA Therapeutics Stock Down 8.1 %

Shares of LVTX stock traded down $0.09 on Monday, reaching $1.02. The stock had a trading volume of 360,841 shares, compared to its average volume of 527,437. LAVA Therapeutics has a 12 month low of $1.00 and a 12 month high of $6.47. The firm has a market capitalization of $25.86 million, a price-to-earnings ratio of -1.08 and a beta of 0.43. The firm’s 50-day moving average is $1.69 and its two-hundred day moving average is $1.82.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.